SCHEMBL7438290

SCHEMBL7438290

CON(C)C(=O)[C@@H](N)Cc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 3/20 0.56
ALPI P09923 1/20 0.56
PKM P14618 1/20 0.56
PTGS1 P23219 1/20 0.56
XIAP P98170 1/20 0.56
LAP3 P28838 1/20 0.50
FAAH O00519 1/20 0.50
SLC15A1 P46059 1/20 0.49
LTA4H P09960 1/20 0.46
HPGD P15428 1/20 0.46
SLC1A3 P43003 2/20 0.45
SLC1A2 P43004 2/20 0.45
SLC1A1 P43005 2/20 0.45
HDAC8 Q9BY41 1/20 0.44
SRR Q9GZT4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7269254 1.00 SLC7A5 (0.56) SLC7A5ALPIPKMPTGS1XIAP
Hydrochloric Acid SCHEMBL6161681 0.98 SLC7A5 (0.54) SLC7A5ALPIPKMPTGS1XIAP
Hydrochloric Acid SCHEMBL1126065 0.98 SLC7A5 (0.54) SLC7A5ALPIPKMPTGS1XIAP
Trifluoroacetic Acid SCHEMBL9725806 0.93 ALPI (0.49) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL7801253 0.88 LTA4H (0.58) PTGS1LAP3LTA4H
SCHEMBL9248667 0.85 SLC7A5 (0.58) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL7032300 0.84 LNPEP (0.45) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL5885156 0.83 LTA4H (0.52) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL7842354 0.83 FAAH (0.47) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL30959049 0.83 ALPI (0.63) SLC7A5ALPIPKMPTGS1XIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11718585-B2 Bis-cyclic guanidines as antibacterial agents UNIVERSITY OF SOUTH FLORIDA (US) 2023-08-08 US disclosed
US-11718585-B2 Bis-cyclic guanidines as antibacterial agents UNIVERSITY OF SOUTH FLORIDA (US) 2023-08-08 US disclosed
US-20220119352-A1 BIS-CYCLIC GUANIDINES AS ANTIBACTERIAL AGENTS NATIONAL SCIENCE FOUNDATION 2022-04-21 US disclosed
US-11214550-B2 Bis-cyclic guanidines as antibacterial agents UNIVERSITY OF SOUTH FLORIDA (US) 2022-01-04 US disclosed
US-20200231572-A1 NOVEL BIS-CYCLIC GUANIDINES AS ANTIBACTERIAL AGENTS NATIONAL SCIENCE FOUNDATION 2020-07-23 US disclosed
WO-1994019329-A1 SUBSTITUTED CYCLIC CARBONYLS AND DERIVATIVES THEREOF USEFUL AS RETROVIRAL PROTEASE INHIBITORS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1994-09-01 WO disclosed
EP-0607334-A1 CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS. DU PONT MERCK PHARMA (US) 1994-07-27 EP disclosed
WO-1993007128-A1 CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1993-04-15 WO disclosed
US-5106835-A Hypotensive agents AMERICAN CYANAMID COMPANY (US) 1992-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119352-A1 BIS-CYCLIC GUANIDINES AS ANTIBACTERIAL AGENTS GMPS, CGAS, GDA SLC7A5 2627/4885ALPI 2554/4885PKM 3888/4885
US-11718585-B2 Bis-cyclic guanidines as antibacterial agents GMPS, CGAS, GDA SLC7A5 2627/4885ALPI 2554/4885PKM 3888/4885
US-11214550-B2 Bis-cyclic guanidines as antibacterial agents GMPS, CGAS, GDA SLC7A5 2627/4885ALPI 2554/4885PKM 3888/4885
US-20200231572-A1 NOVEL BIS-CYCLIC GUANIDINES AS ANTIBACTERIAL AGENTS GMPS, CGAS, GDA SLC7A5 2376/4885ALPI 3046/4885PKM 3938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.